|
|
|
| Feasibility analysis of Montelukast Sodium as an adjuvant treatment for Mycoplasma pneumonia in children |
| TAO Meng-jie |
| Department of Pediatrics,the Second People′s Hospital of Longgang District,Guangdong Province,Shenzhen 518112,China |
|
|
|
|
Abstract Objective To investigate the feasibility of Montelukast Sodium as an adjuvant treatment in children with Mycoplasma pneumonia by observing their clinical manifestations.Methods Sixty-two children with Mycoplasma pneumonia who were treated in our hospital from August 2014 to July 2016 were selected as subjects.They were divided into the control group (n=30)and observation group (n=32)according to the random number table method.In the control group,pediatric patients were treated with intravenous infusion of Azithromycin and aerosol inhalation of Budesonide,while in the observation group,on the basis of the control group,Montelukast Sodium as oral administration was added.The relative clinical data including total therapeutic effectiveness rate,remission time of relevant symptoms,hospital stay,incidence of complications,and blood gas analysis were observed and recorded in the two groups.Results The therapeutic effectiveness rate in the observation group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).The remission time of cough,temperature lowering,disappearance of rales and hospital stay in the observation group were all shorter compared with those in the control group,the incidence of extrapulmonary complications was also lower than that of the control group,and the differences were statistically significant(P＜0.05).The forced expiratory volume in one second(FEV1),the forced expiratory volume in one second/forced vital capacity (FEV1/FVC),maximum expiratory flow (PEF)were all superior to those in the control group,and the differences were statistically significant(P＜0.05).The content of PO2in the observation group was higher than that in the control group,and the content of PCO2was lower than that in the control group,which were displayed statistical significance(P＜0.05).Conclusion In the treatment of children with Mycoplasma pneumonia,Montelukast Sodium can obtain a remarkable effect by greatly promoting therapeutic progress and improving the relevant clinical symptoms,and facilitating the recovery of lung function in children in high safety,which can be popularized and applied in clinic.
|
|
|
|
|
|
| [1] |
刘德二.顺尔宁治疗儿童支原体肺炎的疗效及安全性分析[J].中国妇幼保健，2015，30（9）：1384-1386.
|
| [2] |
马玉萍.阿奇霉素联合小儿清肺颗粒治疗儿童肺炎支原体肺炎疗效观察[J].中国中西医结合儿科学，2016，8（1）：56-58.
|
| [3] |
张霞，石在新.阿奇霉素联合炎琥宁治疗小儿支原体肺炎的临床效果分析[J].中国当代医药，2014，21（5）：73-77.
|
| [4] |
刘维军.阿奇霉素联孟鲁合司特治疗小儿支原体肺炎的临床疗效分析[J].航空航天医学杂志，2014，25（4）：522-524.
|
| [5] |
樊成.阿奇霉素在小儿支原体肺炎应用中的研究进展[J].微量元素与健康研究，2017，34（4）：72-74.
|
| [6] |
魏琦.氨溴特罗联合孟鲁司特治疗小儿咳嗽变异性哮喘[J].医药论坛杂志，2015，36（1）：64-65.
|
| [7] |
褚明慧.孟鲁司特钠联合卡介菌多糖核酸治疗小儿变异性哮喘的哮喘的效果观察[J].中国当代医药，2016，23（5）：23-25.
|
| [8] |
谢伊玲.孟鲁司特钠联合硫酸沙丁胺醇气雾剂（万托林）雾化吸入在治疗小儿咳嗽变异性哮喘的临床疗效分析[J].中国医药科学，2016，6（1）：74-77.
|
| [9] |
方玉婷，姜玲，史天陆，等.孟鲁司特钠佐治儿童肺炎支原体肺炎的疗效与安全性meta分析[J].医学研究与教育，2014，31（5）：29-33.
|
| [10] |
张颖.孟鲁斯特治疗小儿咳嗽变异性哮喘的疗效及安全性[J].实用临床医药杂志，2015，19（11）：145-146.
|
| [11] |
孙频.浅析阿奇霉素联合其他抗生素药物治疗小儿支原体肺炎的疗效[J].临床医药文献杂志，2016，3（37）：7304-7305.
|
| [12] |
王宋青，施益农.热毒宁联合阿奇霉素对支原体肺炎患儿炎性因子及临床疗效的影响[J].广西医学，2016，38（8）：1078-1080.
|
| [13] |
王颖，路广秀.热毒宁联合阿奇霉素治疗小儿化脓性扁桃体炎 128 例临床观察[J].中医药导报，2015，21（23）：74-76.
|
| [14] |
李国君，莫秀嫦，叶晓霓.顺尔宁对肺炎支原体肺炎患儿肺功能及血清细胞因子水平变化的影响[J].齐齐哈尔医学院学报，2016，37（31）：3877-3879.
|
| [15] |
成琳.顺尔宁与布地奈德联用对哮喘患儿的疗效及FEV1、FVC、Eos水平的影响分析[J].北方药学，2016，13（3）：48-49.
|
| [16] |
卢珍.60例小儿肺炎支原体肺炎临床治疗分析[J].中外医学研究，2017，15（14）：137-138.
|
| [17] |
胡婷，钟亮，杨薇斯，等.小儿哮喘治疗中采用白三烯受体拮抗剂顺尔宁的临床效果[J].中国医药科学，2017，7（9）：75-77.
|
| [18] |
李大元，薛洁，陆金星.孟鲁司特钠结合红霉素对小儿支原体肺炎患者临床症状及并发症的作用探讨[J].中外医学研究，2017，15（13）：136-138.
|
| [19] |
张华俐，王超，张蕊，等.发光免疫分析仪联合检测超敏C反应蛋白、降钙素原及免疫功能对小儿肺炎诊断的价值[J].中国医学装备，2016，13（12）：109-112.
|
|
|
|
